Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Malaria Vaccines Market In 2029?
In recent years, the malaria vaccines market has witnessed rapid growth. With an anticipation to rise from $4.7 billion in 2024 to $6.24 billion in 2025, the market would exhibit a compound annual growth rate (CAGR) of 32.7%. The significant expansion recorded during the historic period has its roots in numerous factors like a high prevalence of malaria, worldwide health initiatives, availability of funding and grants, initiatives towards controlling malaria, and support from government and regulatory bodies.
The malaria vaccines market size is expected to see exponential growth in the next few years. It will grow to $20.19 billion in 2029 at a compound annual growth rate (CAGR) of 34.1%. The growth in the forecast period can be attributed to global elimination goals, expanded access programs, increasing vaccine coverage, global vaccine alliances, climate change impact. Major trends in the forecast period include technological innovations, public-private partnerships, international collaboration, advancements in vaccine technology, advancements in vaccine technology.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13698&type=smp
What Are the Core Market Drivers Propelling Growth in the Malaria Vaccines Industry?
The malaria vaccine market’s growth is predicted to be driven by an increase in mosquito-borne diseases. These diseases encompass a wide range of illnesses that result from the bite of an infected mosquito. The RTS, S/AS01 (RTS, S) malaria vaccine plays a significant role in mitigating the effects of these diseases by priming the immune system to recognize and combat the parasites. As an example, a World Health Organization report in November 2023 revealed that there were approximately 249 million malaria cases worldwide in 2022, marking an increase of 5 million cases from the previous year. Furthermore, Pakistan saw around 2.6 million cases in 2022, which is a significant leap from the 500,000 cases reported in 2021. Consequently, the increase in mosquito-borne diseases is accelerating the expansion of the malaria vaccine market.
How Is the Malaria Vaccines Market Segmented?
The malaria vaccinesmarket covered in this report is segmented –
1) By Agent: Plasmodium Falciparum; Plasmodium Vivax; Anopheles Species
2) By Vaccine Type: Pre-Erythrocytic; Erythrocytic; Multi-antigen; Other Vaccines
3) By Route Of Administration: Intramuscular; Subcutaneous; Intradermal; Other Routes
4) By Distribution Channel: Public; Private
Subsegments:
1) By Plasmodium Falciparum: RTS,S/AS01 Vaccine; Other Experimental Vaccines
2) By Plasmodium Vivax: Candidate Vaccines In Development; Combination Vaccines
3) By Anopheles Species: Transmission-Blocking Vaccines; Vector Control Approaches
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13698&type=smp
Which Regions Are Driving the Next Phase of the Malaria Vaccines Market Growth?
North America was the largest region in the malaria vaccines market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the malaria vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Malaria Vaccines Market?
Several leading companies within the malaria vaccine market are forging innovative products, such as child-specific malaria vaccines, in an effort to broaden their consumer base, accelerate sales, and boost revenue. These vaccines, developed for mosquito-transmitted diseases, are immuno-formulations aimed at preventing the diseases carried by mosquitoes. They specifically target Plasmodium falciparum, which is the most lethal malaria parasite worldwide and particularly predominant in Africa. For instance, Malawi, an East African nation, in conjunction with the World Health Organization, an intergovernmental entity based in Switzerland, rolled out Africa’s inaugural child-focused malaria vaccine in November 2022. The unique appeal of the RTSS vaccine, designed for young children, rests in its potential to reduce fatalities from mosquito-induced disease. The vaccine has already been piloted on over a million children in Ghana, Kenya, and Malawi. Despite its modest effectiveness rate of 30%, there is hopeful speculation that it could help save the lives of the 400,000 people who die from malaria annually.
View the full report here:
https://www.thebusinessresearchcompany.com/report/malaria-vaccines-global-market-report
How Is the Malaria Vaccines Market Defined and What Are Its Core Parameters?
Malaria vaccines are specific vaccines designed to prevent malaria, a potentially deadly mosquito-borne infectious disease caused by parasites from the Plasmodium genus. These vaccines aim to provide immunity against the plasmodium parasites that cause malaria.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13698
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
